Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tasimelteon for Non-24-Hour Sleep-Wake Disorder in Totally Blind Subjects
2011-000281-35Phase 3Active
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Non-24-hour sleep-wake disorder (N24SWD) and circadian rhythm sleep disorder (CRSD) comparing Tasimelteon 20 mg with Placebo (2 arms). Primary endpoint: Entrainment of circadian melatonin rhythm. Started Mar 2011; status: active.
02
Drugs
tasimelteon
03
Conditions
Non-24-hour sleep-wake disorder (N24SWD)circadian rhythm sleep disorder (CRSD)
Beyond the preview
Go deeper on 2011-000281-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000281-35.